Sign In
19 Jan 2022 12:56
19 January 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Director/PDMR Shareholding
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, advises that Stephen West, Executive Chairman has purchased ordinary shares in the Company in the market, as detailed below:
Name | Number of Ordinary Shares | Average Price Paid Per Share | Total Consideration Paid |
Stephen West | 150,000 | 10.36 pence | £15,542.10 |
Following the above purchase of shares, Mr West holds interests in the following Company securities:
Name | Number of Ordinary Shares Held | % of Issued Share Capital | Number of Warrants Held |
Stephen West | 4,550,000 | 6.33 % | 7,500,000 |
4,399,000 of Mr West's shares are held in the name of Cresthaven Investments Pty Ltd ATF the Bellini Trust.
Enquiries:
Roquefort Therapeutics plc | |
Stephen West (Chairman) | +44 (0)20 3290 9339
|
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale
Optiva Securities Limited (Broker) |
+44 (0)20 7466 5000 |
Christian Dennis | +44 (0)20 3411 1881 |
For further information on Roquefort Therapeutics, please visit www.roquefortinvest.com and @RoquefortTherap on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company's wholly owned subsidiary, Lyramid Pty Ltd ("LYRAMID"), is a pre-clinical biotech company focused on developing first in class Midkine inhibiting RNA therapeutics drugs for the treatment of cancer, chronic inflammatory, autoimmune disorder and COVID-19. Recent progress within mRNA therapeutics has led to a reduction in drug development timelines and costs, increasing the chance of early value creation.
Through extensive research resulting in validation through publication in over 1,000 scientific journals, Lyramid has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Lyramid holds the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). LYRAMID's pre-clinical programme is currently underway with an initial focus on cancer (including immunotherapy resistance) and COVID-19.
This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").
The notification below, made in accordance with the requirements of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Stephen West | |
2 | Reason for the notification | ||
a) | Position/status | Executive Chairman | |
b) | Initial notification /Amendment | Initial | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Roquefort Therapeutics plc | |
b) | LEI | 254900P4SISIWOR9RH34 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.01 par value
ISIN: GB00BMDQ2T15 | |
b) | Nature of the transaction | Purchase of 150,000 ordinary shares | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
10.31 pence per share 10.46 pence per share | 100,000 50,000 | ||
d | Aggregated information - Aggregated volume - Price |
- 150,000 - 10.36p | |
e) | Date of the transactions | 19 January 2022 | |
f) | Place of the transactions | London Stock Exchange (XLON); Main Market | |
Follow the stocks
